Anavex Life Sciences (NASDAQ: AVXL)
Anavex Life Sciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Anavex Life Sciences Company Info
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
News & Analysis
Wall Street Thinks This Small-Cap Stock Can Quadruple in Value
The company generates no revenue, but it may be worth taking a chance on as it possesses lots of upside.
Why Shares of Anavex Life Sciences Rose 12.4% in February
The company's first-quarter earnings report detailed positive news regarding its pipeline.
Is Anavex Life Sciences Stock a Buy Now?
A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business.
This Short-Squeeze Candidate Could Actually Pan Out in the Long Run
Short-sellers have piled into this clinical-stage biopharma stock.
Why Anavex Life Sciences Stock Bolted Higher in January
The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results.
Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why
The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data.
Is Anavex Life Sciences a Buy?
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's.
Is Anavex Life Sciences a Smart Stock to Buy Now?
The company's Alzheimer's disease drug just succeeded in a clinical trial. Or did it?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.